tirzepatide summit trial cardiovascular outcomes Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular Tirzepatide Reduces Heart Failure Events

Gamma-butyrobetaine (GBB)

The approval comes just four months after the regulator greenlit Narcan, a 4-mg naloxone hydrochloride nasal spray, as the first OTC naloxone product

Dulaglutide (Trulicity) Dosage and Administration Dulaglutide is administered once a week, at any time of day, with or without meals

Even small reductions in daily movement, fewer steps, skipping workouts, more sedentary weekends, can narrow the deficit

Even after approval, medications are still monitored closely by the MHRA and doctors for safety

Clinical data reveals average triglyceride reductions of 2030% in patients treated with semaglutide, with greater improvements in those starting with the highest triglyceride concentrations